ET is a chronic myeloproliferative disorder rarely evolving into AML, sometimes preceded by a myelodysplastic syndrome (MDS). Such transformations mostly occur in patients treated with radiophosphorous ( 32 P) or alkylating agents, especially busulfan. Recently, concern has also arisen about the longterm safety of hydroxyurea (HU). Pipobroman (PI), a well tolerated and simple to use drug, constitutes a valid alternative to those cytoreductive treatments. The present study reports on 155 ET patients treated at our institution from 1985 to 1995, and monitored until December 2000. A good control of thrombocytosis was achieved with PI as the only treatment in 106 patients and with HU in 23 patients. Twenty-six patients received no treatment. After a median follow-up of 104 months, seven patients (four treated with HU, and three with PI) developed AML whereas one patient treated with PI developed MDS. A significant difference in progression-free survival was observed between HU-and PI-treated patients (P = 0.004). A short-arm deletion of chromosome 17 was most frequently detected in HU-treated patients, while a long-arm trisomy of chromosome 1 and a monosomy 7q were seen in PI-treated patients. No TP53 mutation was discovered in the six patients studied (two HU-treated and four PI-treated). We conclude that these cytogenetic abnormalities are not linked to the natural history of the disease, but rather that they might be induced by the cytoreductive treatment.
Introduction
Essential thrombocythemia is a chronic myeloproliferative disorder with a relatively benign clinical course. However, some patients are asymptomatic while others experience life-threatening thromboembolic episodes.
1,2 Among these last patients, cytoreduction is mandatory in those above 60 years of age and those with a platelet count above 1000 × 10 9 /l. 3 The drug preferentially given to achieve this goal is hydroxyurea (HU), because of its high effectiveness in reducing the incidence of thrombotic complications and its low leukemogenic potential. 4 Other myelosuppressive treatments consisting of radiophosphorous ( 32 P) or alkylating agents (especially busulfan (BU)) have also been used, but it has been reported that they may increase the risk of developing acute myeloid leukemia (AML). 5, 6 In fact, until recently, progression of ET to AML, preceded or not by myelodysplasia (MDS), has been observed in 3% to 4% of patients, mostly those treated with ( alkylating agents. 7 In 1998, however, concern also arose about the long-term safety of HU treatment: it was reported that 13% of HU-treated ET patients developed MDS/AML or solid tumors. 8 Interestingly, most of these patients carried a 17p deletion (17p−). This chromosome abnormality, due to unbalanced translocations or to monosomy 17 or to i(17q), is associated with the presence of pseudo Pelger-Huét hypolobulation and small vacuoles in neutrophils and with TP53 mutation. It was suggested that 17p− identifies a new and specific morphologic-cytogenetic-molecular entity within the group of secondary MDS/AMLs. In contrast, only anedoctal cytogenetic information is available for ET patients treated with pipobroman (PI) alone who developed MDS/AML. 9 Here we review cases of MDS/AML occurring in 155 ET patients diagnosed and cytogenetically studied at our institution from 1985 to 1995 and monitored until December 2000. Eight cases of MDS/AML were observed: four in patients treated with HU and four in patients treated with PI.
Materials and methods

Diagnosis
All 155 patients were diagnosed at the Division of Hematology, Policlinico San Matteo IRCCS, Pavia, from January 1985 to December 1995. ET was diagnosed according to the Polycythemia Vera Study Group (PVSG) criteria. 10 A bone marrow core biopsy was part of the diagnostic work-up in each patient.
Treatments
Cytoreductive therapy was started when the patient met one or all of the following criteria: platelet count greater than 1 × 10 12 /l, age Ͼ60, previous thrombosis. In most patients induction treatment consisted of PI, given at the dose of 1 mg/kg/day orally until response. The maintenance dose varied between 0.3 and 0.6 mg/kg/day, according to response. In another smaller group of patients, induction treatment consisted of HU with a starting dose of 15 mg/kg/day until response. Response to treatment was defined as a reduction of platelets to 400 × 10 9 /l. No patients initially treated with PI or HU received both drugs or any other drugs at any time during the course of the disease.
No fixed criteria were followed to administer antiaggregating agents, but every patient received antiaggregating therapy with aspirin, dypiridamole, or ticlopidine at the onset of the disease. 
Follow-up
Patients were seen at our out-patient clinic every year, unless any disease complication had occurred. MDS and AML were diagnosed according to French-American-British (FAB) criteria.
Cytogenetics, fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction (RT PCR)
Cytogenetic studies were carried out on bone marrow cells at diagnosis and during the follow-up, using a trypsin-Giemsa banding technique. Metaphase cells were examined from short-term unstimulated cultures. Chromosome abnormalities were defined according to ISCN. 11 FISH, aimed at confirming the short-arm deletion of chromosome 17, was performed on cytogenetic preparations as previously reported. 12 A digoxygenated p53 DNA probe (17p13.1) (red signal) was applied simultaneously with a biotinylated alphoid probe specific for the same chromosome (green signal) (Oncor, Gaithersburg, MD, USA) and used as an internal control to demonstrate that hybridization had effectively taken place. After applying a binomial distribution, 12 the cut-off value for p53 interphase FISH was fixed at 0.8% for p53 monosomy and at 0.3% for p53 trisomy as the highest number of cells lacking a p53 signal was three in normal subjects, probably because of a hybridization failure and as the highest number of cells with three p53 signals was one in the same subjects. After examining 200 cells from ten normal controls 12 the cut-off value for p53 interphase FISH was fixed at 4% by adding three times the standard deviation to the mean percentage of cells with two signals due to the internal control and only one signal due to the p53 DNA probe. The cut-off value for p53 trisomy on interphase cells was determined in the same way and was fixed at 2%.
In order to exclude the presence of a bcr/abl transcript, an RT PCR assay was carried out at diagnosis for every patient diagnosed from 1994 onwards and during follow-up in all others in whom the clinical diagnosis was made before 1994. The assay was performed as already described. 13 
Polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and DNA direct sequencing
Our PCR SSCP assay was carried out as previously reported 14 and its sensitivity permits the detection of a TP53 mutation restricted to 5-10% of the cell population examined, as established by control dilutional analysis using a cell line containing a previously characterized TP53 mutation. 15 Samples were investigated for mutations in exons 5 to 8. DNA direct sequencing was performed as previously described. 15 Both strands were sequenced for each DNA fragment analyzed.
Statistical analysis
Cumulative incidence of disease progression over 5, 10 and 15 years and incidence rates (person/year) have been calculated and reported for each group of patients. Initially, we drew the survival curves and compared the differences between different groups of patients by means of the log-rank Leukemia test. In order to control for potential confounding elements, we next constructed a multivariate poisson regression model. The following variables were first introduced into the model: sex (male or female), age group (less than or greater/equal to 65 years of age), type of treatment (HU or PI), treatment duration (less than or greater/equal to 9 years). A Poisson regression model was fitted and the likelihood-ratio test was used to determine if there was a statistical significant difference in the likelihood of estimated models. Incidence rate ratios (IRR) and their 95% confidence intervals (CI) for the best fit model have been reported.
All the statistical tests were two-sided; a P value less then 0.05 was considered as statistically significant. Statistical univariate analysis was performed on Statistica (StatSoft Inc., release 5.5; Tulsa, OK, USA) and multivariate analysis on Stata (Stata Corp, release 7.0, TX, USA) software packages.
Results
Clinical and hematological features of MDS/AML after ET
Patients' clinico-biological features at the onset of the disease and treatments are listed in Table 1 . After a median follow-up of 104 months (range 8-240) eight of the 155 patients (5.1%) progressed to MDS/AML. Their clinico-biological features are summarized in Table 2 . They included five women and three men with a median age of 56 years (range 40-78). Four patients received HU for 53, 94, 47 and 96 months, respectively, while four received PI for 36, 53, 83 and 113 months, respectively. The median interval between ET diagnosis and MDS/AML evolution was 89 months (range 47-114). Seven patients had AML without a preceeding MDS: one was classified as M1, two as M2, three as M4 and one as M7. One patient had MDS, subclassified as refractory anemia with excess of blasts (RAEB). After the diagnosis of MDS/AML was made, six patients were given intensive chemotherapy and two monochemotherapy with 6-thioguanine. A short-term partial response with 50% reduction of marrow blasts was achieved in only two patients, both treated with intensive chemotherapy. 
Cytogenetics, FISH and PCR-SSCP result
Chromosome analysis was successful in all eight MDS/AML patients. A mixture of karyotypically normal and abnormal cells was observed in two, a completely abnormal karyotype in six (Table 2) . Two patients showed two chromosome defects, while the remaining six had a complex cytogenetic pattern (>three abnormalities). A rearrangement of the short arms of chromosome 17 was detected in all four patients previously treated with HU. Three of them showed a 17p deletion, which was confirmed by FISH with the p53 DNA probe on both metaphase and interphase cells (58-78% abnormal nuclei). The DNA PCR-SSCP assay revealed the absence of any TP53 mutation/overexpression in the only patient studied (no material was available for the other two patients). Morphologically, all three patients displayed the pseudo Pelger-Huét hypolobulation and small vacuoles in at least 5% of neutrophils. The remaining patient presented two cell lines: one carrying a t(3;6)(q26;p22) translocation, the other, without the translocation, having a complex karyotype. In this patient, FISH with the p53 DNA and the 17␣ probes demonstrated two red and two green signals (two normal chromosomes 17) in 68% of the cells examined, and three red and three green signals in the remaining 32%. In these cells the third red and green spots were localized on add(17)(p13). In all four patients the rearrangement of number 17 was never a unique abnormality; it was often associated with an interstitial long-arm deletion of chromosome 5. Morphologically the patient did not show the Pelger-Huét anomaly.
All four PI-treated patients presented an abnormal karyotype with chromosomes 1 and 7 most frequently involved in unbalanced rearrangements. In particular, two patients showed an unbalanced translocation dic(1;7), one presented a rearrangement of band 1p11 and a trisomy 1q, the last one a translocation t (1;3) . In all these patients, FISH with the p53 DNA probe gave normal results on both metaphase and interphase cells and DNA PCR-SSCP assay demonstrated no mutation of 
Statistical analysis
The proportion of patients surviving without progression by Kaplan-Meier is shown in Figure 1 . A statistically significant difference was observed between HU-vs PI-treated patients (P = 0.04). Cumulative incidences of disease progression in patients treated with HU vs PI are reported in Table 3 . The Table 3 Cumulative incidence of disease progression over 5, 10 and 15 years and incidence rate (person/year) incidence rate (person/year) was 0.016 vs 0.003. IRR and 95% CI for the best fit models are reported in Table 4 . The likelihood ratio test was statistically significant (P = 0.019) only when HU-vs PI-treated patients were examined.
Discussion
In our ET patients, cytogenetically and molecularly studied from the onset of disease and with a median follow-up of 104 months (range 8-240), a clinical evolution into MDS/AML occurred with an incidence of 5.1%, similar to that reported in the literature. [5] [6] [7] [8] 16, 17 To the best of our knowledge, this is the first cytogenetic study dealing with MDS/AML in ET patients previously treated with PI. Until now such an evolution has been described mostly in patients who had been given 32 P or alkylating agents, especially busulfan. 6, 7 Recently, it has also been reported that long-term treatment with HU may favor an evolution of ET into MDS/AML, 8 marked by a 17p deletion (17p−) with loss of one TP53 allele, vacuolated neutrophils and presentation of the Pelger-Huét anomaly. Even if this reported association still needs to be proved, 18, 19 four of our eight AMLs having evolved from ET occurred in subjects treated with HU and three of them developed a 17p−. In every case FISH with the p53 DNA probe detected only one red signal, confirming loss of one TP53 allele. A DNA PCR-SSCP assay for the TP53 mutation, carried out in one of the three patients (no material was available in the other two cases), detected no mutation, despite the fact that the subjects presented hypolobulated neutrophils and a complex karyotype with 17p and 5q deletions. These last biological features are all typically associated with TP53 mutation/overexpression 20, 21 and suggest a possible cooperation between TP53 inactivation and an as yet unidentified gene residing within band 5q13.3. 22 The biological features of our patient are similar to those already reported in two other previously described patients with no TP53 mutation 23 and in a more recent one having an apparent 17p13 loss but a wild-type TP53 gene. 21 In the fourth patient, cytogenetics and FISH identified three chromosomes 17 with three p53 signals in 32% of the cells screened. On PCR-SSCP analysis no TP53 mutation was discovered. Morphologically, the patient did not show the Pelger-Huét anomaly. As far as we know such a cytogenetic pattern has been observed in only one other patient having an AML following untreated ET. Also, this subject did not show any peculiar morphological or immunophenotypic characteristics. 24 Few reports in the literature have dealt with MDS/AML in ET patients treated with PI alone. 10, 25 Moreover, in most of them the chromosome pattern has not been investigated. PI is Leukemia a bromide derivative of piperazine which, although its formula is close to that of alkylating agents, appears to act mainly as a metabolic competitor of pyrimidine bases. It inhibits the activity of DNA and RNA polymerases. PI has not been extensively employed in ET; on the contrary the notion of its effectiveness in polycythemia vera (PV) goes back to the 1980s. 26, 27 In the present study, two PI-treated patients carried the unbalanced translocation t(1;7)(p11;q11), that should always be defined as dic(1;7)(p11;q11) on the basis of FISH analysis. 28 Dicentric chromosomes normally result in the loss of the arms reciprocal to those forming the dicentric region. This does not apply to dic(1;7) which is associated with two apparently normal chromosomes 1 and results in a trisomy for the long arm of chromosome 1(+1q) and in a monosomy for the long arm of chromosome 7(7q−) as seen in our two patients. A recent study has demonstrated that dic(1;7) is significantly more common in secondary MDS/AML than in de novo cases, and is significantly related to previous treatment with alkylating agents. 29 The time range from the exposure to mutagenic agents to the development of MDS/AML is usually between 2 and 14 years. 30 Our patients received PI for 36 and 83 months and the time interval from ET diagnosis to MDS/AML development was 69 and 84 months. Therefore, both might well be therapy-related AMLs. However, a recent large cytogenetic study of 165 patients affected by myelofibrosis with myeloid metaplasia has revealed that the dic(1;7) was relatively frequent (7% of all abnormal cases). 31 None of the patients in the latter series received treatment with PI. It is therefore not unexpected to detect such an abnormality in clonally evolved ET. In fact, a dic(1;7) was previously reported in a chemotherapy naive patient with ET which evolved first in myelofibrosis and then to acute leukemia (M0). 32 However, none of our dic(1;7) patients presented a phase of myelofibrosis preceding AML development. A third patient carried a trisomy 1q, due to +add(1)(p11), and the fourth presented a t(1;3)(p36;q21).
The concern over drug leukemogenicity into ET is unlikely to be resolved in the absence of a prospective study because leukemic transformation into ET is a time-dependent variable and it is difficult to identify an appropriate control group for a retrospectively selected study population. There are numerous published reports of leukemic transformation in ET in the absence of previous cytoreductive therapy. 33 Furthermore, treatment-unrelated leukemic transformations have previously been associated with complex cytogenetic abnormalities. 24, 34 Therefore, in this clinical setting it is difficult to differentiate a natural sequela from a treatment-related event. However, in the present series none of our untreated patients experienced a progression into MDS/AML.
The possible association between HU therapy and 17p− anomaly is still an unanswered question. In fact, an elegant analysis using Sterkers' own data 8 revealed a more impressive association of 17p− with advanced age rather than HU treatment, 19 a correlation we were unable to find in our series. Furthermore, the 17p− anomaly was often associated with other complex abnormalities and was not found to be specific to either HU treatment or ET. 23 In the latter series of 25 17p− cases, 14 were observed in patients with either ET or PV. Four of these 14 cases never received HU therapy and most of the 10 cases who had prior exposure to HU were also treated with other agents including PI and 32 P. As far as PI is concerned, a study on ET patients detected an incidence of progression into MDS/AML of 0% and 16%, respectively, when PI was used alone or after the use of other agents (usually HU). 8 In a prospective report on PV patients, comparing PI with HU, the leukemogenic risk was approximately 10% at the 13th year, with no significant difference between the two drugs. 35 In the present study, the incidence of MDS/AML in ET patients treated with PI alone was 3.7%, while that in ET patients treated with HU alone was misleading, since it was unusually high, possibly because of the small number of patients. In fact, in studies on a significant number of patients with a similar follow-up duration or receiving HU for over 10 years, an evolution into MDS/AML was observed in only 3.5% or in none of the patients, respectively. 8, 36 In the present study, we observed a significant difference in progression-free survival between HU-and PI-treated patients (P = 0.04), with a cumulative incidence higher in HU-treated patients. Furthermore, the relative risk of developing MDS/AML was six times higher in patients treated with HU compared to those who received PI.
In conclusion, our study suggests that 17p−, trisomy 1q and monosomy 7q are not related to the natural history of ET and to its genetic instability, but rather that they might be induced by the type of cytoreductive therapy given. A 17p deletion was discovered only in HU-treated patients and it developed solely at the time of disease evolution, similar to what was reported in another study. 9 A more recent report has further stressed that TP53 mutations are drug-related and not independent of the type of chemotherapy. 21 Deletions or loss of 5q, of 17p and a complex karyotype were all closely related to TP53 mutations and to previous chemotherapy with alkylating agents, especially cyclophosphamide. Our three 17p− patients presented similar cytogenetic and morphological features even though the one patient tested for the TP53 mutation carried only the wild-type gene. A different conclusion was achieved by a recent study which detected TP53 mutations in untreated patients also.
14 However, in the present study none of our untreated patients with a sufficiently long follow-up developed MDS/AML. Moreover, among the 11 patients examined with p53 FISH during the follow-up (reported in Table 1 ), none of the eight untreated patients and neither of the two patients treated with PI presented a 17p− at any time during the course of the disease, while the remaining patient, the only one treated with HU, developed the deletion just at the time of MDS/AML evolution.
A trisomy 1q was discovered only in patients treated with PI. The fact that it was due to a dic(1;7) in two patients and to a +add(1)(p11) in the remaining one suggests that PI, although acting in a slightly different way, might cause dicentric chromosome formation through a demethylation of the centromeric regions, just as alkylating agents do.
